Author: admin

The European Commission approved Tresiba ® and Ryzodeg ® for the treatment of diabetes. Copenhagen, January 2013.- the European Commission has approved the develo-location of Tresiba ® (insulin degludec) and Ryzodeg ® (degludec/insulin aspart insulin) for the treatment of diabetes in adults. This approval is extended to the 27 Member States of the European Union. Tresiba ®, commercial name of degludec insulin, is an analog of insulin of new generation, which is administered once a day and has a long-term profile. In studies following a methodology of treatment up to target, which were presented to the application for approval of the drug and that Tresiba ® was compared with insulin glargine, Tresiba ® demonstrated a lower risk of overall hypoglycaemia and nocturnal hypoglycemia, at the time that successfully reached the same reductions in HbA1c. In addition, with a duration of more than 42 hours action, Tresiba ® is the first basal insulin that people with diabetes offers the possibility of adjusting the time of injection according to your needs. For his part, Ryzodeg ®, trade name for degludec/insulin aspart insulin, is composed of analogue basal insulin from new generation degludec in a soluble formulation with insulin aspart. Ryzodeg ® can be administered once or twice daily with the main meals. In studies following a methodology of treatment up to target, which were presented to the application for approval of...